SII Correlates 30-Day Mortality in Postop ICU Patients
ClinicalTrials.gov Studies
Summary
A new observational clinical study registered on ClinicalTrials.gov is investigating whether the Systemic Immuno-Inflammation Index (SII), calculated from neutrophil, lymphocyte, and platelet counts at ICU admission, correlates with 30-day mortality in postoperative adult ICU patients. The study focuses on geriatric anesthesia patients and will analyze the prognostic value of SII as a non-invasive biomarker. This registry entry documents the study's objectives and methodology rather than a regulatory action or clinical outcome.
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
This document registers a new observational clinical trial (NCT07544719) on ClinicalTrials.gov. The study will calculate the Systemic Immuno-Inflammation Index using complete blood count parameters (neutrophils, lymphocytes, platelets) at ICU admission and analyze its relationship with 30-day patient mortality. The research focuses on postoperative adult ICU patients under geriatric anesthesia conditions.
Healthcare providers, clinical investigators, and researchers monitoring inflammatory biomarker studies may find this registry relevant to ongoing work in critical care prognosis. The study's findings may inform future evidence on non-invasive biomarkers for ICU patient risk stratification, though this registry entry itself creates no compliance obligations.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Systemic Immun Inflamation Score Corelation in Postoperative Patients Prognosis
Observational NCT07544719 Kind: OBSERVATIONAL Apr 22, 2026
Abstract
The Systemic Immuno-Inflammation Index (SII) is a ratio derived from complete blood count parameters (neutrophils, lymphocytes, platelets) and is a non-invasive and easily calculable biomarker. The SIPI effectively reflects both local and systemic inflammatory responses in the human body. It has been used to predict and evaluate the prognosis of various solid tumors such as gastric cancer, non-small cell lung cancer, and colorectal cancer. Furthermore, the SIPI has been shown to have significant prognostic value in cardiovascular and cerebrovascular diseases. In this study, the SIPI will be calculated using laboratory data at the time of admission to the intensive care unit, and the relationship between the obtained values and the 30-day mortality status of the patients will be analyzed.
Conditions: Geriatric Anesthesia, Postop Adult ICU Patients
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.